Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topigen Pharmaceuticals, a clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, has appointed Mark Parry-Billings as its new CEO.
Subscribe to our email newsletter
Dr Parry-Billings joined Topigen in 2007 as chief development officer and expanded his role to lead the company’s operations in early 2008.
Previously, Dr Parry-Billings was European director and member of the board of pSiMedica. Dr Parry-Billings has a PhD and was a post-doctoral fellow in biochemistry at the University of Oxford.
The company also received C$11 million ahead of schedule from its previously announced series C venture financing round of C$26 million in August 2007, which will provide further funding for key product opportunities.
Gary Lessing, chairman of the board of directors, said: “With Mark’s extensive knowledge of respiratory product development and strong industry experience, he is an obvious choice to lead Topigen during its next phase of development.”